Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

Formulation Design, Optimization and In Vivo Evaluations of an α-Tocopherol-Containing Self-Emulsified Adjuvant System using Inactivated Influenza Vaccine.

Lodaya RN, Kanitkar AP, Friedrich K, Henson D, Yamagata R, Nuti S, Mallett CP, Bertholet S, Amiji MM, O'Hagan DT.

J Control Release. 2019 Oct 31;316:12-21. doi: 10.1016/j.jconrel.2019.10.042. [Epub ahead of print]

PMID:
31678654
2.

Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): A phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccine.

Gonzalez-Lopez A, Oostendorp J, Koernicke T, Fadini T, D'Oro U, Baker S, O'Hagan DT, Del Giudice G, Siena E, Finco O, Medini D.

Clin Immunol. 2019 Oct 24;209:108275. doi: 10.1016/j.clim.2019.108275. [Epub ahead of print]

3.

The droplet size of emulsion adjuvants has significant impact on their potency, due to differences in immune cell-recruitment and -activation.

Shah RR, Taccone M, Monaci E, Brito LA, Bonci A, O'Hagan DT, Amiji MM, Seubert A.

Sci Rep. 2019 Aug 8;9(1):11520. doi: 10.1038/s41598-019-47885-z.

4.

Mannosylation of LNP Results in Improved Potency for Self-Amplifying RNA (SAM) Vaccines.

Goswami R, Chatzikleanthous D, Lou G, Giusti F, Bonci A, Taccone M, Brazzoli M, Gallorini S, Ferlenghi I, Berti F, O'Hagan DT, Pergola C, Baudner BC, Adamo R.

ACS Infect Dis. 2019 Sep 13;5(9):1546-1558. doi: 10.1021/acsinfecdis.9b00084. Epub 2019 Jul 23.

PMID:
31290323
5.

Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want.

HogenEsch H, O'Hagan DT, Fox CB.

NPJ Vaccines. 2018 Oct 10;3:51. doi: 10.1038/s41541-018-0089-x. eCollection 2018. Review.

6.

Stable Nanoemulsions for the Delivery of Small Molecule Immune Potentiators.

Lodaya RN, Brito LA, Wu TYH, Miller AT, Otten GR, Singh M, O'Hagan DT.

J Pharm Sci. 2018 Sep;107(9):2310-2314. doi: 10.1016/j.xphs.2018.05.012. Epub 2018 Jun 5.

PMID:
29883663
7.

The Preparation and Physicochemical Characterization of Aluminum Hydroxide/TLR7a, a Novel Vaccine Adjuvant Comprising a Small Molecule Adsorbed to Aluminum Hydroxide.

Malyala P, Laera D, Cianetti S, Bufali S, Aggravi M, Ianni E, Judge C, Otten G, Singh M, O'Hagan DT.

J Pharm Sci. 2018 Jun;107(6):1577-1585. doi: 10.1016/j.xphs.2018.01.024. Epub 2018 Feb 6.

PMID:
29421216
8.

Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs.

Francica JR, Zak DE, Linde C, Siena E, Johnson C, Juraska M, Yates NL, Gunn B, De Gregorio E, Flynn BJ, Valiante NM, Malyala P, Barnett SW, Sarkar P, Singh M, Jain S, Ackerman M, Alam M, Ferrari G, Salazar A, Tomaras GD, O'Hagan DT, Aderem A, Alter G, Seder RA.

Blood Adv. 2017 Nov 17;1(25):2329-2342. doi: 10.1182/bloodadvances.2017011411. eCollection 2017 Nov 28. Erratum in: Blood Adv. 2018 Mar 13;2(5):516.

9.

Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model.

Misiak A, Leuzzi R, Allen AC, Galletti B, Baudner BC, D'Oro U, O'Hagan DT, Pizza M, Seubert A, Mills KHG.

Vaccine. 2017 Sep 18;35(39):5256-5263. doi: 10.1016/j.vaccine.2017.08.009. Epub 2017 Aug 18.

10.

Towards an evidence based approach for the development of adjuvanted vaccines.

O'Hagan DT, Friedland LR, Hanon E, Didierlaurent AM.

Curr Opin Immunol. 2017 Aug;47:93-102. doi: 10.1016/j.coi.2017.07.010. Epub 2017 Jul 26. Review.

11.

Mechanism of action of mRNA-based vaccines.

Iavarone C, O'hagan DT, Yu D, Delahaye NF, Ulmer JB.

Expert Rev Vaccines. 2017 Sep;16(9):871-881. doi: 10.1080/14760584.2017.1355245. Epub 2017 Jul 28. Review.

PMID:
28701102
12.

Optimizing adjuvants for intradermal delivery of MenC glycoconjugate vaccine.

Donadei A, Balocchi C, Romano MR, Panza L, Adamo R, Berti F, O'Hagan DT, Gallorini S, Baudner BC.

Vaccine. 2017 Jul 13;35(32):3930-3937. doi: 10.1016/j.vaccine.2017.06.018. Epub 2017 Jun 20.

PMID:
28645718
13.

Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake.

Liang F, Lindgren G, Sandgren KJ, Thompson EA, Francica JR, Seubert A, De Gregorio E, Barnett S, O'Hagan DT, Sullivan NJ, Koup RA, Seder RA, Loré K.

Sci Transl Med. 2017 Jun 7;9(393). pii: eaal2094. doi: 10.1126/scitranslmed.aal2094.

PMID:
28592561
14.

Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines.

Buonsanti C, Balocchi C, Harfouche C, Corrente F, Galli Stampino L, Mancini F, Tontini M, Malyala P, Bufali S, Baudner B, De Gregorio E, Valiante NM, O'Hagan DT, Rappuoli R, D'Oro U.

Sci Rep. 2016 Jul 21;6:29063. doi: 10.1038/srep29063.

15.

The adjuvant effect of TLR7 agonist conjugated to a meningococcal serogroup C glycoconjugate vaccine.

Donadei A, Balocchi C, Mancini F, Proietti D, Gallorini S, O'Hagan DT, D'Oro U, Berti F, Baudner BC, Adamo R.

Eur J Pharm Biopharm. 2016 Oct;107:110-9. doi: 10.1016/j.ejpb.2016.07.004. Epub 2016 Jul 5.

PMID:
27388628
16.

Incorporation of Phosphonate into Benzonaphthyridine Toll-like Receptor 7 Agonists for Adsorption to Aluminum Hydroxide.

Cortez A, Li Y, Miller AT, Zhang X, Yue K, Maginnis J, Hampton J, Hall de S, Shapiro M, Nayak B, D'Oro U, Li C, Skibinski D, Mbow ML, Singh M, O'Hagan DT, Cooke MP, Valiante NM, Wu TY.

J Med Chem. 2016 Jun 23;59(12):5868-78. doi: 10.1021/acs.jmedchem.6b00489. Epub 2016 Jun 13.

PMID:
27270029
17.

The preparation and characterization of PLG nanoparticles with an entrapped synthetic TLR7 agonist and their preclinical evaluation as adjuvant for an adsorbed DTaP vaccine.

Bruno C, Agnolon V, Berti F, Bufali S, O'Hagan DT, Baudner BC.

Eur J Pharm Biopharm. 2016 Aug;105:1-8. doi: 10.1016/j.ejpb.2016.05.013. Epub 2016 May 17.

PMID:
27224856
18.

Multiplex immunoassay for in vitro characterization of acellular pertussis antigens in combination vaccines.

Agnolon V, Bruno C, Galletti B, Mori E, Ugozzoli M, Pergola C, O'Hagan DT, Baudner BC.

Vaccine. 2016 Feb 17;34(8):1040-6. doi: 10.1016/j.vaccine.2016.01.012. Epub 2016 Jan 17.

PMID:
26784684
19.

The potential of adjuvants to improve immune responses against TdaP vaccines: A preclinical evaluation of MF59 and monophosphoryl lipid A.

Agnolon V, Bruno C, Leuzzi R, Galletti B, D'Oro U, Pizza M, Seubert A, O'Hagan DT, Baudner BC.

Int J Pharm. 2015 Aug 15;492(1-2):169-76. doi: 10.1016/j.ijpharm.2015.06.030. Epub 2015 Jul 3.

PMID:
26149936
20.

New generation adjuvants--from empiricism to rational design.

O'Hagan DT, Fox CB.

Vaccine. 2015 Jun 8;33 Suppl 2:B14-20. doi: 10.1016/j.vaccine.2015.01.088. Review.

PMID:
26022561
21.

Are we entering a new age for human vaccine adjuvants?

O'Hagan DT, Fox CB.

Expert Rev Vaccines. 2015 Jul;14(7):909-11. doi: 10.1586/14760584.2015.1043273. Epub 2015 May 6.

PMID:
25947042
22.

Fabrication of cell culture-derived influenza vaccine dissolvable microstructures and evaluation of immunogenicity in guinea pigs.

Bonificio A, Ghartey-Tagoe E, Gallorini S, Baudner B, Chen G, Singh P, O'Hagan DT, Kommareddy S.

Vaccine. 2015 Jun 9;33(25):2930-8. doi: 10.1016/j.vaccine.2015.04.059. Epub 2015 Apr 27.

PMID:
25930118
23.

Rational Design of Adjuvant for Skin Delivery: Conjugation of Synthetic β-Glucan Dectin-1 Agonist to Protein Antigen.

Donadei A, Gallorini S, Berti F, O'Hagan DT, Adamo R, Baudner BC.

Mol Pharm. 2015 May 4;12(5):1662-72. doi: 10.1021/acs.molpharmaceut.5b00072. Epub 2015 Apr 20.

PMID:
25867449
24.

Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization.

Francica JR, Sheng Z, Zhang Z, Nishimura Y, Shingai M, Ramesh A, Keele BF, Schmidt SD, Flynn BJ, Darko S, Lynch RM, Yamamoto T, Matus-Nicodemos R, Wolinsky D; NISC Comparative Sequencing Program, Nason M, Valiante NM, Malyala P, De Gregorio E, Barnett SW, Singh M, O'Hagan DT, Koup RA, Mascola JR, Martin MA, Kepler TB, Douek DC, Shapiro L, Seder RA.

Nat Commun. 2015 Apr 10;6:6565. doi: 10.1038/ncomms7565.

25.

Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus.

Bagnoli F, Fontana MR, Soldaini E, Mishra RP, Fiaschi L, Cartocci E, Nardi-Dei V, Ruggiero P, Nosari S, De Falco MG, Lofano G, Marchi S, Galletti B, Mariotti P, Bacconi M, Torre A, Maccari S, Scarselli M, Rinaudo CD, Inoshima N, Savino S, Mori E, Rossi-Paccani S, Baudner B, Pallaoro M, Swennen E, Petracca R, Brettoni C, Liberatori S, Norais N, Monaci E, Bubeck Wardenburg J, Schneewind O, O'Hagan DT, Valiante NM, Bensi G, Bertholet S, De Gregorio E, Rappuoli R, Grandi G.

Proc Natl Acad Sci U S A. 2015 Mar 24;112(12):3680-5. doi: 10.1073/pnas.1424924112. Epub 2015 Mar 9.

26.

The development of self-emulsifying oil-in-water emulsion adjuvant and an evaluation of the impact of droplet size on performance.

Shah RR, Dodd S, Schaefer M, Ugozzoli M, Singh M, Otten GR, Amiji MM, O'Hagan DT, Brito LA.

J Pharm Sci. 2015 Apr;104(4):1352-61. doi: 10.1002/jps.24337. Epub 2015 Jan 19.

PMID:
25600347
27.

The impact of size on particulate vaccine adjuvants.

Shah RR, O'Hagan DT, Amiji MM, Brito LA.

Nanomedicine (Lond). 2014 Dec;9(17):2671-81. doi: 10.2217/nnm.14.193.

PMID:
25529570
28.

Rational design of small molecules as vaccine adjuvants.

Wu TY, Singh M, Miller AT, De Gregorio E, Doro F, D'Oro U, Skibinski DA, Mbow ML, Bufali S, Herman AE, Cortez A, Li Y, Nayak BP, Tritto E, Filippi CM, Otten GR, Brito LA, Monaci E, Li C, Aprea S, Valentini S, Calabrό S, Laera D, Brunelli B, Caproni E, Malyala P, Panchal RG, Warren TK, Bavari S, O'Hagan DT, Cooke MP, Valiante NM.

Sci Transl Med. 2014 Nov 19;6(263):263ra160. doi: 10.1126/scitranslmed.3009980.

29.

A cationic nanoemulsion for the delivery of next-generation RNA vaccines.

Brito LA, Chan M, Shaw CA, Hekele A, Carsillo T, Schaefer M, Archer J, Seubert A, Otten GR, Beard CW, Dey AK, Lilja A, Valiante NM, Mason PW, Mandl CW, Barnett SW, Dormitzer PR, Ulmer JB, Singh M, O'Hagan DT, Geall AJ.

Mol Ther. 2014 Dec;22(12):2118-29. doi: 10.1038/mt.2014.133. Epub 2014 Jul 16.

30.

Designing and building the next generation of improved vaccine adjuvants.

Brito LA, O'Hagan DT.

J Control Release. 2014 Sep 28;190:563-79. doi: 10.1016/j.jconrel.2014.06.027. Epub 2014 Jul 3. Review.

PMID:
24998942
31.

Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses.

Gallorini S, Taccone M, Bonci A, Nardelli F, Casini D, Bonificio A, Kommareddy S, Bertholet S, O'Hagan DT, Baudner BC.

Vaccine. 2014 Apr 25;32(20):2382-8. doi: 10.1016/j.vaccine.2013.12.043. Epub 2014 Jan 13.

PMID:
24434044
32.

Vaccine adjuvant formulations: a pharmaceutical perspective.

Brito LA, Malyala P, O'Hagan DT.

Semin Immunol. 2013 Apr;25(2):130-45. doi: 10.1016/j.smim.2013.05.007. Epub 2013 Jul 12. Review.

PMID:
23850011
33.

The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect.

Calabro S, Tritto E, Pezzotti A, Taccone M, Muzzi A, Bertholet S, De Gregorio E, O'Hagan DT, Baudner B, Seubert A.

Vaccine. 2013 Jul 18;31(33):3363-9. doi: 10.1016/j.vaccine.2013.05.007. Epub 2013 May 16.

PMID:
23684834
34.

Influenza subunit vaccine coated microneedle patches elicit comparable immune responses to intramuscular injection in guinea pigs.

Kommareddy S, Baudner BC, Bonificio A, Gallorini S, Palladino G, Determan AS, Dohmeier DM, Kroells KD, Sternjohn JR, Singh M, Dormitzer PR, Hansen KJ, O'Hagan DT.

Vaccine. 2013 Jul 25;31(34):3435-41. doi: 10.1016/j.vaccine.2013.01.050. Epub 2013 Feb 8.

PMID:
23398932
35.

The history of MF59(®) adjuvant: a phoenix that arose from the ashes.

O'Hagan DT, Ott GS, Nest GV, Rappuoli R, Giudice GD.

Expert Rev Vaccines. 2013 Jan;12(1):13-30. doi: 10.1586/erv.12.140. Review.

PMID:
23256736
36.

Nonviral delivery of self-amplifying RNA vaccines.

Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, Cu Y, Beard CW, Brito LA, Krucker T, O'Hagan DT, Singh M, Mason PW, Valiante NM, Dormitzer PR, Barnett SW, Rappuoli R, Ulmer JB, Mandl CW.

Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14604-9. doi: 10.1073/pnas.1209367109. Epub 2012 Aug 20.

37.

MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine.

Singh M, Kazzaz J, Ugozzoli M, Baudner B, Pizza M, Giuliani M, Hawkins LD, Otten G, O'Hagan DT.

Hum Vaccin Immunother. 2012 Apr;8(4):486-90. doi: 10.4161/hv.19229.

PMID:
22832252
38.

The vaccine adjuvant alum inhibits IL-12 by promoting PI3 kinase signaling while chitosan does not inhibit IL-12 and enhances Th1 and Th17 responses.

Mori A, Oleszycka E, Sharp FA, Coleman M, Ozasa Y, Singh M, O'Hagan DT, Tajber L, Corrigan OI, McNeela EA, Lavelle EC.

Eur J Immunol. 2012 Oct;42(10):2709-19. doi: 10.1002/eji.201242372. Epub 2012 Aug 6.

39.

The mechanism of action of MF59 - an innately attractive adjuvant formulation.

O'Hagan DT, Ott GS, De Gregorio E, Seubert A.

Vaccine. 2012 Jun 19;30(29):4341-8. doi: 10.1016/j.vaccine.2011.09.061. Review. Erratum in: Vaccine. 2013 Apr 3;31(14):1877.

PMID:
22682289
40.

Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens.

Kommareddy S, Baudner BC, Oh S, Kwon SY, Singh M, O'Hagan DT.

J Pharm Sci. 2012 Mar;101(3):1021-7. doi: 10.1002/jps.23019. Epub 2011 Dec 20.

PMID:
22190403
41.

The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant.

Jain S, O'Hagan DT, Singh M.

Expert Rev Vaccines. 2011 Dec;10(12):1731-42. doi: 10.1586/erv.11.126. Review.

PMID:
22085176
42.

Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations.

Vecchi S, Bufali S, Skibinski DA, O'Hagan DT, Singh M.

J Pharm Sci. 2012 Jan;101(1):17-20. doi: 10.1002/jps.22759. Epub 2011 Sep 14. Review.

PMID:
21918987
43.

Flow cytometry: an alternative method for direct quantification of antigens adsorbed to aluminum hydroxide adjuvant.

Ugozzoli M, Laera D, Nuti S, Skibinski DA, Bufali S, Sammicheli C, Tavarini S, Singh M, O'Hagan DT.

Anal Biochem. 2011 Nov 15;418(2):224-30. doi: 10.1016/j.ab.2011.07.012. Epub 2011 Jul 22.

PMID:
21820996
44.

An alternative renewable source of squalene for use in emulsion adjuvants.

Brito LA, Chan M, Baudner B, Gallorini S, Santos G, O'Hagan DT, Singh M.

Vaccine. 2011 Aug 26;29(37):6262-8. doi: 10.1016/j.vaccine.2011.06.067. Epub 2011 Jun 30.

PMID:
21723355
45.

Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88.

Seubert A, Calabro S, Santini L, Galli B, Genovese A, Valentini S, Aprea S, Colaprico A, D'Oro U, Giuliani MM, Pallaoro M, Pizza M, O'Hagan DT, Wack A, Rappuoli R, De Gregorio E.

Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11169-74. doi: 10.1073/pnas.1107941108. Epub 2011 Jun 20.

46.

Combination vaccines.

Skibinski DA, Baudner BC, Singh M, O'Hagan DT.

J Glob Infect Dis. 2011 Jan;3(1):63-72. doi: 10.4103/0974-777X.77298.

47.

MF59 adjuvant: the best insurance against influenza strain diversity.

O'Hagan DT, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G.

Expert Rev Vaccines. 2011 Apr;10(4):447-62. doi: 10.1586/erv.11.23. Review.

PMID:
21506643
48.

Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes.

Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M, O'Hagan DT, De Gregorio E, Seubert A, Wack A.

Vaccine. 2011 Feb 17;29(9):1812-23. doi: 10.1016/j.vaccine.2010.12.090. Epub 2011 Jan 6.

PMID:
21215831
49.

Bioadhesive delivery systems for mucosal vaccine delivery.

Baudner BC, O'Hagan DT.

J Drug Target. 2010 Dec;18(10):752-70. doi: 10.3109/1061186X.2010.529143. Epub 2010 Nov 2. Review.

PMID:
21039314
50.

A two-stage strategy for sterilization of poly(lactide-co-glycolide) particles by γ-irradiation does not impair their potency for vaccine delivery.

Jain S, Malyala P, Pallaoro M, Giuliani M, Petersen H, O'Hagan DT, Singh M.

J Pharm Sci. 2011 Feb;100(2):646-54. doi: 10.1002/jps.22306.

PMID:
20665902

Supplemental Content

Loading ...
Support Center